|Other Names||Glutamate receptor ionotropic, delta-2, GluD2, GluR delta-2 subunit, GRID2, GLURD2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13471b was selected from the C-term region of GRID2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists. Promotes synaptogenesis and mediates the D-Serine- dependent long term depression signals and AMPA receptor endocytosis of cerebellar parallel fiber-Purkinje cell (PF-PC) synapses through the beta-NRX1-CBLN1-GRID2 triad complex (PubMed:27418511).|
|Cellular Location||Cell membrane; Multi-pass membrane protein. Cell junction, synapse, postsynaptic cell membrane; Multi-pass membrane protein|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Human glutamate receptor delta-2 (GRID2) is a relativelynew member of the family of ionotropic glutamate receptors whichare the predominant excitatory neurotransmitter receptors in themammalian brain. GRID2 is a predicted 1,007 amino acid proteinthat shares 97% identity with the mouse homolog which is expressedselectively in cerebellar Purkinje cells. A point mutation inmouse GRID2, associated with the phenotype named 'lurcher', in theheterozygous state leads to ataxia resulting from selective,cell-autonomous apoptosis of cerebellar Purkinje cells duringpostnatal development. Mice homozygous for this mutation dieshortly after birth from massive loss of mid- and hindbrain neuronsduring late embryogenesis. This strongly suggests a role for GRID2in neuronal apoptotic death.
Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Joubert, B.R., et al. Genome Med 2 (3), 17 (2010) :Kakegawa, W., et al. J. Neurosci. 28(6):1460-1468(2008)Sonoda, T., et al. Biochem. Biophys. Res. Commun. 350(3):748-752(2006)Yap, C.C., et al. Biochem. Biophys. Res. Commun. 301(4):1122-1128(2003)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.